RANDAL J KIRK
CIK 1091823 · Executive Chairman · last filed 2026-03-16
RANDAL J KIRK is an Executive Chairman who has filed 232 SEC Form 4 insider transactions across 12 companies since 2007. The most recent filing, for PGEN, was dated Mar 30, 2026. Across all open-market trades the lifetime net is +$457.2M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $3.3M across reported positions. 232 SEC filings were submitted jointly with INTREXON CORP.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.32M
12
232
$457.19M
Filer Profile
RADFORD, VA 24141
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PGEN | Director | 477,492 | $6.85 | $3.27M | $42.06M | 40 | 2026-03-16 |
| AQB | 10%+ Owner | 375 | $1.22 | $458 | $714.5K | 11 | 2021-11-24 |
| PRECIGEN, INC. (XON) Delisted | Executive Chairman | 176,628 | — | — | $206.60M | 80 | 2020-01-07 |
| Theriva Biologics, Inc. (SYN) Delisted | 10%+ Owner | 23,449 | $1.02 | $23.9K | $20.80M | 4 | 2019-04-03 |
| Alaunos Therapeutics, Inc. (ZIOP) Delisted | Director | 3,601,994 | $0.87 | $3.12M | $43.29M | 20 | 2018-10-09 |
| PRPO | 10%+ Owner | 1,689 | $27.32 | $46.1K | -$10.1K | 3 | 2018-08-30 |
| HALOZYME THERAPEUTICS, INC. (HTI) Delisted | 10%+ Owner | 3,917,041 | — | — | $39.79M | 39 | 2018-08-28 |
| Fibrocell Science, Inc. (FCSC) Delisted | 10%+ Owner | 426,719 | — | — | $41.32M | 4 | 2017-03-10 |
| OGEN | 10%+ Owner | 805 | $0.48 | $385 | $8.55M | 3 | 2016-07-05 |
| Precipio, Inc. (TBIO) Delisted | 10%+ Owner | 5,593 | $0.00 | $1 | $4.47M | 5 | 2016-01-11 |
| CLINICAL DATA INC (CLDA) Delisted | Director | 0 | — | — | $49.60M | 10 | 2011-04-12 |
| NEW RIVER PHARMACEUTICALS INC (NRPH) Delisted | Chairman, President and CEO | — | — | — | $0 | 1 | 2007-01-31 |
Recent Filings
232 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-30 | PGEN | Notice (144) | −4,772,781 | -$17.52M | EDGAR |
| 2026-03-16 | PGEN | Exer (M) | +143,678 | $0 | EDGAR |
| 2026-03-12 | PGEN | Grant (A) | +28,490 | $100.0K | EDGAR |
| 2025-12-22 | PGEN | Notice (144) | −1,900,036 | -$8.21M | EDGAR |
| 2025-12-22 | PGEN | Sell (S) | −1,900,036 | -$7.94M | EDGAR |
| 2025-11-21 | PGEN | Sell (S) | −2,966,293 | -$12.29M | EDGAR |
| 2025-11-20 | PGEN | Notice (144) | −942,832 | -$3.84M | EDGAR |
| 2025-11-20 | PGEN | Notice (144/A) | −1,086,153 | -$4.58M | EDGAR |
| 2025-11-19 | PGEN | Notice (144) | −1,086,153 | -$4.58M | EDGAR |
| 2025-09-30 | PGEN | Notice (144) | −1,809,667 | -$6.57M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.